

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S18 7	50759	Interferon OR IFN	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:45
S18 8	41928	tau	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:45
S18 9	142	S187(n3)S188	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:45
S19 0	2434967	MS or "multiple sclerosis"	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:45
S19 1	142	S189 and S190	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:46
S19 2	205379	oral	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:46
S19 3	117	S191 and S192	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 09:47
S19 4	40951	autoimmune	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:48
S19 5	2439642	S190 or S194	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:48
S19 6	10308	IL-10 or "Interleukin-10"	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:49
S19 7	275966	gamma	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:49
S19 8	1584	S187(N3)S197	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:51
S19 9	58	S196(n5)S198	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 08:56

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L4	23649	liu.in.	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 09:59
L5	138	Chih-ping.in.	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 09:59
L6	29	I4 and I5	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 10:12
L7	19	lorelie.in. and villarete.in.	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 10:17
L8	12	I5 and I7.	US-PGPUB; USPAT; EPO; JPO	AND	ON	2006/11/20 10:17

Document ID	Document Type	Issue Date	Pages	Title	Current Class	Current Xref	Inventor	Abstract
US 7083782 B2	USPAT	20060801	34	Method of treatment using interferon-tau	424/85.4		Liu, Chih-Ping et al.	Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN-tau. are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN-tau. is described. IFN-tau. is administered at a dose sufficient to achieve an up-regulation of IL-10 in the blood, relative to the IL-10 level in the absence of IFN-tau.
US 20040247565 A1	US-PGPUB	20041209	35	Method of treatment using interferon-tau	424/85.2	424/85.4	Liu, Chih-Ping et al.	A method of modulating the IL-10/IL-12 blood ratio in subjects suffering from an autoimmune disorder is described. The method involves administering interferon-tau in a dose sufficient to modulate the patient's IL-10/IL-12 blood ratio, to prevent on-set, to prevent progression, or to treat an autoimmune condition.
US 20050084478 A1	US-PGPUB	20050421	38	Combination therapy using interferon-tau	424/85.4	514/423; 514/449; 514/460; 514/548	Liu, Chih-Ping et al.	Methods of treatment comprised of a combination treatment regimen of interferon-tau (IFN-tau.) and one or more additional agents are described. In the combined treatment method, IFN-tau. is orally administered to the patient. One or more additional treatment agents are administered prior to, concurrent with, or subsequent to oral administration of IFN-tau... In one embodiment, the combined treatment regimen is for treatment of an autoimmune condition, such as multiple sclerosis, and interferon-tau is administered in combination with a second therapeutic, autoimmune treatment agent. In another embodiment, the combined treatment regimen involves administering an agent that protects, or stabilizes interferon-tau after oral administration, optionally in combination with another treatment agent.
US 20050118137 A1	US-PGPUB	20050602	35	Method of treatment using interferon-tau	424/85.4	514/18; 514/49	Liu, Chih-Ping et al.	A method of increasing IL-10/IFN-gamma. ratio in subjects suffering from an autoimmune condition or a viral infection is described. IFN-tau. is administered in a dose sufficient to increase the IL-10/IFN-gamma. blood ratio, to prevent on-set, to prevent progression, or to treat these conditions.

Document ID	Document Type	Issue Date	Pages	Title	Current Class	Current Xref	Inventor	Abstract
US 20050118138 A1	US-PGPUB	20050602	34	Method of treatment using interferon-tau	424/85.4		Liu, Chih-Ping et al.	A method of preventing an increase in the blood level of IFN- $\gamma$ in a subject at risk of an elevated IFN- $\gamma$ blood level due to (i) administration of a therapeutic agent or (ii) a disease condition is described. The method includes administering interferon-tau (IFN-tau.) at a dosage sufficient to maintain or to decrease the IFN- $\gamma$ blood level in a patient being treated with an agent that causes a rise in IFN- $\gamma$ blood level or suffering from a condition that causes a rise in IFN- $\gamma$ blood level.
US 20050142109 A1	US-PGPUB	20050630	35	Method of treatment using interferon-tau	424/85.4		Liu, Chih-Ping et al.	Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN-tau. are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN-tau. is described. IFN-tau. is administered at a dose sufficient to achieve an up-regulation of IL-10 in the blood, relative to the IL-10 level in the absence of IFN-tau.
US 20050201981 A1	US-PGPUB	20050915	26	Method of optimizing treatment with interferon-tau	424/85.4		Liu, Chih-Ping et al.	Improvements in a method of treating a human disease or condition responsive to continued and periodic interferon-tau administration in humans are provided, by adjusting the dose administered to the patient in accordance with the patient's serum IL-10 response.
US 20050226845 A1	US-PGPUB	20051013	21	Method of treatment using interferon-tau	424/85.4		Liu, Chih-Ping et al.	Methods of treating a disease or condition responsive to interleukin-10 therapy in a mammal are provided. In one form, a method includes orally administering a therapeutically effective amount of interferon tau to the mammal. In other forms of the invention, the method includes administering a second therapeutic agent to the mammal in addition to interleukin-10 either simultaneously or sequentially.
US 20050265968 A1	US-PGPUB	20051201	13	Method of treating IL-10 deficiency	424/85.4		Liu, Chih-Ping et al.	A method for treating an IL-10 deficiency in a human subject is described, where a person having an IL-10 deficiency is identified and treated with interferon-tau (IFN-tau.) at a dose sufficient to increase the IL-10 level.

Document ID	Document Type	Issue Date	Pages	Title	Current Class	Current Xref	Inventor	Abstract
US 20060078942 A1	US-PGPUB	20060413	35	Method of treatment using interferon-tau	435/6	435/69.1	Liu; Chih-Ping et al.	Methods of treating an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN:tau. are described. More specifically, a method of up-regulating the IL-10 level in patients afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation by administering IFN:tau. is described. IFN:tau. is administered at a dose sufficient to achieve an up-regulation of IL-10 in the blood, relative to the IL-10 level in the absence of IFN:tau..
US 20060134750 A1	US-PGPUB	20060622	37	Method of treatment using interferon-tau	435/69.1	435/6	Liu; Chih-Ping et al.	Methods of treating an autoimmune condition by administering IFN:tau. are described. IFN:tau. is administered orally at a dose sufficient to achieve obtain a desired clinical endpoint, such as a reduction in new contrast-enhanced brain lesions in multiple sclerosis patients.
US 20060257363 A1	US-PGPUB	20061116	35	Treatment using an interferon	424/85.4	424/85.6; 424/85.7	Liu; Chih-Ping et al.	Methods of treatment using a high oral dose of an interferon are described. An interferon, such as interferon-alpha-, interferon-beta, or interferon-tau, is administered to persons afflicted with an autoimmune condition, a viral infection, or a condition of cellular proliferation.

Document ID	Document Type	Issue Date	Pages	Title	Current Class	Current Xref	Inventor	Abstract
US 5668117 A	USPAT	19970916	37	Methods of treating neurological diseases and etiologically related symptomatology using carbonyl trapping agents in combination with previously known medicaments	514/55	436/518; 436/74; 514/1; 514/23; 514/54; 514/811; 514/866; 514/878; 514/879; 514/903; 514/912; 536/11; 536/20	Shapiro; Howard K. et al.	Therapeutic compositions comprising an effective amount of at least one carbonyl trapping agent alone or in combination with a therapeutically effective of a co-agent or medicament are disclosed. The compositions are used to treat a mammal suffering from a neurological disease characterized by covalent bond crosslinking between the nerve cells, other cellular structures and their intracellular and extracellular components, with disease induced carbonyl-containing aliphatic or aromatic hydrocarbons present in mammals.
US 6204022 B1	USPAT	20010320	25	Low-toxicity human interferon-alpha analogs	435/69.51	424/85.4; 424/85.7; 530/351; 536/23.52	Johnson; Howard M. et al.	The invention describes a method of reducing the cytotoxicity of interferon-alpha by making defined amino acid substitutions in the N-terminal portion of the polypeptide sequence. Also described are human interferon-alpha analogs with low cytotoxicity, and therapeutic applications of the low toxicity interferon-alpha analogs.
US 6759431 B2	USPAT	20040706	144	Compositions and methods for treating or preventing diseases of body passageways	514/449	424/403; 424/426; 424/501	Hunter; William L. et al.	The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.
US 6822097 B1	USPAT	20041123	212	Compounds and methods of uses	546/153	546/155; 546/157; 546/158	Norman; Mark H. et al.	Selected compounds are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
US 20020052404 A1	US-PGPUB	20020502	140	Compositions and methods for treating or preventing diseases of body passageways	514/449	424/486	Hunter, William L. et al.	The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

Document ID	Document Type	Issue Date	Pages	Title	Current Class	Current Xref	Inventor	Abstract
US 20030143197 A1	US-PGPUB	20030731	17	Method for treating diseases with omega interferon	424/85.2	424/161.1; 424/85.4; 514/400	Moran, S. Mark et al.	<p>A method of treating an immunologic, proliferative, or infectious disease in a warm-blooded animal is disclosed. The method comprises administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal, which dosage and activity for the disease state treated is higher than would be well-tolerated based on data for non-omega IFNs. The omega IFN is administered alone or in combination with a therapeutically effective amount of at least one adjunctive therapeutic agent. Also disclosed is an article of manufacture useful for treating an immunologic, proliferative, or infectious disease, which article comprises (1) omega IFN in a form suitable for administering a therapeutically effective amount of the omega IFN to the subject in order to induce the desired therapeutic response (2) instructions for administering the omega IFN as desired, that is higher than would be well-tolerated based on data for non-omega IFNs.</p>
US 20040029832 A1	US-PGPUB	20040212	26	Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases	514/58		Zeldis, Jerome B.	<p>Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.</p>

Document ID	Document Type	Issue Date	Pages	Title	Current Class	Current Xref	Inventor	Abstract
US 20040220202 A1	US-PPGPUB	20041104	74	Neuroprotective and anti-proliferative compounds	514/280	514/410; 546/41; 548/416	Jaquith, James B. et al.	This invention features ring-substituted pyrrolo-.beta.-carboline derivatives and ring-substitution and structural derivatives of 3-(1H-indol-3-yl)-1H-pyrrole-2,5-dione of formulas I-III, which are useful as neuroprotective and anti-proliferative compounds. Also disclosed are methods for the preparation of these compounds, selected biological profiles and uses of these compounds in the treatment of various neurodegenerative and inflammatory diseases of the human nervous system and in the treatment of various other proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation. 1
US 20040224023 A1	US-PPGPUB	20041111	141	Compositions and methods for treating or preventing diseases of body passageways	424/486		Hunter, William L. et al.	The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

? b 155,5,73,34

[File 155] MEDLINE(R) 1950-2006/Nov 14

(c) format only 2006 Dialog. All rights reserved.

\*File 155: NLM will not provide updates from November 16-20. Please see HELP NEWS 154 for details.

[File 5] Biosis Previews(R) 1969-2006/Nov W2

(c) 2006 The Thomson Corporation. All rights reserved.

[File 73] EMBASE 1974-2006/Nov 20

(c) 2006 Elsevier B.V. All rights reserved.

[File 34] SciSearch(R) Cited Ref Sci 1990-2006/Nov W2

(c) 2006 The Thomson Corp. All rights reserved.? d s

Set Items Description

S1 480850 S INTERFERON OR IFN

S2 91517 S TAU

S3 1995 S S1 (2N) S2

S4 507076 S MS OR "MULTIPLE SCLEROSIS" OR "AUTOIMMUNE DISEASE"

S5 70 S S3 AND S4

S6 44 RD (unique items)

S7 21 S S6 NOT PY>2000